-
Quest Diagnostics Set to Acquire OhioHealth's Lab Services
2024 Jul 15, 3:56pm | 892Quest Diagnostics (NYSE: DGX) recently announced a definitive agreement to purchase the select assets of OhioHealth's outreach laboratory services business. The transaction will expand access to the company's cost-effective and advanced laboratory services in Ohio. The transaction is likely...
-
Bank of America, Schwab, Morgan Stanley: What To Expect From Tuesday's Earnings
2024 Jul 15, 3:42pm | 592Bank of America Corporation (NYSE:BAC), Charles Schwab Corporation (NYSE:SCHW) and Morgan Stanley (NYSE:MS) are expected to report their second-quarter earnings on Tuesday. Analysts expect Bank of America to post earnings per share (EPS) of 80 cents alongside $22.52 billion in revenue for the...
-
Low Market Volatility to Hurt Schwab's Q2 Earnings
2024 Jul 12, 2:05pm | 902Charles Schwab (NYSE: SCHW) is scheduled to report second-quarter 2024 results on Jul 16, before market open. While the company's earnings are expected to have declined in the quarter on a year-over-year basis, revenues are anticipated to have improved. In the first quarter of 2024, Schwab'...
-
The Bank of New York Mellon Corporation Surpasses Q2 Earnings and Revenue Estimates
2024 Jul 12, 12:05pm | 684The Bank of New York Mellon Corporation (NYSE: BK) came out with quarterly earnings of $1.51 per share, beating the Zacks Consensus Estimate of $1.43 per share. This compares to earnings of $1.38 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report...
-
Conagra Q4 Earnings Top Despite Soft Consumption Trends
2024 Jul 12, 12:00pm | 1070Conagra Brands, Inc. (NYSE: CAG) delivered fourth-quarter fiscal 2024 results, wherein the bottom and top lines declined year over year and the latter missed the Zacks Consensus Estimate. The company continued to witness challenging industry trends, including a slowdown in consumption. Shares of...
-
Here's Why You Should Invest in Beam Therapeutics Now
2024 Jul 12, 11:57am | 862Beam Therapeutics Inc. (NASDAQ: BEAM) is evaluating its leading ex-vivo genome-editing candidate, BEAM-101, in the phase I/II BEACON study for the treatment of adult patients with sickle cell disease, an inherited blood disorder. BEAM's pipeline of gene editing therapies is based on its...
-
PepsiCo Q2 Earnings Beat, Soft QFNA Results Hurt Stock
2024 Jul 11, 3:02pm | 1256PepsiCo, Inc. (NASDAQ: PEP) has reported robust second-quarter 2024 results, wherein earnings surpassed the Zacks Consensus Estimate, while revenues lagged. However, the top and bottom lines improved year over year. The company's results have mainly been aided by improvements in its...
-
Republic Services Stock Gains 32% in a Year: Here's Why
2024 Jul 11, 2:51pm | 626Republic Services (NYSE: RSG) had an impressive run over the past year. In the same time frame, the stock has gained 32% compared with the 21.3% rally of the industry it belongs to and the 26.1% rise of the Zacks S&P 500 composite. RSG's revenues for 2024 and 2025 are anticipated to...
-
Osisko Reports Q2 Preliminary Revenues and Margins
2024 Jul 11, 2:27pm | 686Osisko Gold Royalties (NYSE: OR) reported an 18.6% year-over-year fall in attributable gold equivalent ounces ("GEOs") in the second quarter of 2024. Preliminary revenues from royalties and streams were disclosed at $64.8 million, which suggests a 7.1% increase from the prior-year quarter...
-
Marsh & McLennan Unit Sustains Its Acquisition Spree
2024 Jul 11, 12:31pm | 780Marsh & McLennan Companies, Inc.'s (NYSE: MMC) Marsh McLennan Agency ("MMA"), a division of MMC's Marsh business, recently inked a definitive deal to purchase the Illinois-based leading full-service insurance broker, The Horton Group, Inc. The transaction is expected to be...
-
Zevra Rises on Update on Niemann-Pick Disease Type C Drug
2024 Jul 11, 12:26pm | 753Zevra Therapeutics, Inc. (NASDAQ: ZVRA) announced that the FDA has indicated that it will convene a meeting with the recently formed Genetic Metabolic Diseases Advisory Committee ("GeMDAC") to review the company's new drug application (NDA) for pipeline candidate arimoclomol. The NDA...
-
AZZ Q1 Earnings and Revenues Beat Estimates
2024 Jul 11, 11:47am | 639AZZ (NYSE: AZZ) came out with quarterly earnings of $1.46 per share, beating the Zacks Consensus Estimate of $1.31 per share. This compares to earnings of $1.14 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 11.45...
-
BofA Analysts Expect Robinhood EPS Beat In Q2: Here's Why
2024 Jul 10, 4:48pm | 560BofA Securities analysts who upgraded Robinhood Markets Inc (NASDAQ:HOOD) to a Buy in May are anticipating an earnings beat from the online broker in August. The Details BofA Securities released a research note Wednesday touting Robinhood as well-positioned for both near-term and long-term...
-
UniQure Soars on New Huntington's Disease Study Data
2024 Jul 10, 4:01pm | 1125uniQure N.V. (NASDAQ: QURE) surged 76.5% on Jul 9 after it announced updated interim data, including up to 24 months of follow-up data, from 29 treated patients enrolled in the ongoing early to mid-stage studies of AMT-130 for Huntington's disease in the United States and EU. Results...
-
Athira Completes Dosing in Alzheimer's Study, Stock Up
2024 Jul 10, 3:42pm | 698Athira Pharma, Inc (NASDAQ: ATHA) recently announced that it has dosed the last patient in the phase II/III LIFT-AD study, which is evaluating its pipeline candidate, fosgonimeton for the treatment of mild-to-moderate Alzheimer's disease (AD). Shares of the company were up 29.4%, following the...
Coverage of Earnings Beats.